×
Customize
?
Start
Cancer Types
Quick Links
Award Programs
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873
Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873
Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
Immunotherapy
Wayne Kuznar
Combining two immunotherapies known as checkpoint inhibitors along with best supportive care prolonged life by two and a half months in patients with advanced colorectal cancer that resisted previous treatments.
Alexandra Guadagno
An expert discusses the future of immunotherapy in light of new frontline treatments like Keytruda that have been demonstrating positive results for patients with non–muscle invasive bladder cancer.
Katie Kosko
An expert describes how far the field has come, with two treatments approved and more in the works.
Jessica Skarzynski
One expert weighs in on the use of new immunotherapy agents and combinations in treating non-small cell lung cancer.
Kristie L. Kahl
An integrative model helped to determine which patients with bladder cancer may benefit from checkpoint inhibitor therapy.
Kristie L. Kahl
The Food and Drug Administration granted a priority review to the supplemental biologics license application for Keytruda (pembrolizumab) for the first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).
Brielle Benyon
Only about 4 percent of adults with cancer are treated on clinical trials, according to one expert. Yet, those results are then applied to everybody.
Jarushka Naidoo, M.B.B.Ch.
Immunotherapy can cause some side effects that patients and practitioners should look out for.
Sumanta K. Pal, M.D.
Yervoy plus Opdivo is a good combination for many patients with kidney cancer, though some individuals should steer clear of the regimen.
Maurie Markman, M.D.
When I began my medical oncology career more than 30 years ago, I was determined to be among the first generation of researchers to cure cancer.